Document:

<PAGE>

                                                                    EXHIBIT 10.8

                      PATENT LICENSE AND ROYALTY AGREEMENT

            THIS AGREEMENT (the "Agreement") is made by and between OccuLogix
Corporation. a Florida Corporation (the "Licensee"), and Prof Dr. Richard
Brunner ("Brunner) living in Germany and listed as inventor [along with Prof.
Dr. Helmut Borberg ("Borberg") but who is not yet or currently a party to this
Agreement or other license agreement with OccuLogix] in US patent application
09/000,917, which is the parent application of US letters patent 6,245,038
issued June 12, 2001 (the "Patent").

            WHEREAS, Brunner [and Borberg] are the sole owners of the Patent and
enjoy all of the rights, title and interests therein, and

            WHEREAS, Brunner desires to license any and all of his rights, title
and interests to the Patent and the Patent Rights derived therefrom to Licensee,
and

            WHEREAS, Licensee desires to obtain an exclusive license to all of
Brunner's interests in the Patent and. the Patent Rights derived therefrom and
to exclusively own the License to any and all of his rights, title, interests
and ownership to the Patent and any and all related patents, rights and
inventions that specifically relate to the Patent whether owned now or at any
time in the future by Brunner (the "License"), and

            WHEREAS, Brunner shall be eligible to receive any and all
consideration and compensation from the Licensee, such as those pledged to be
made by the Licensee to Brunner under the terms of this Agreement

            NOW THEREFORE, in consideration for guaranteed Advance Royalty
Payments and Royalty Payments as described below, and other good and valuable
consideration, Brunner does hereby exclusively license, in accordance with the
terms set forth below, unto Licensee, its successors and assigns, Brunner's
entire undivided right, title, ownership and interest in and to the Patent and
the invention(s) therein contained (the "Patent Rights"), throughout the
Territory, to be held and enjoyed by Licensee its successors and assigns, the
same as it would have been held and enjoyed by Brunner if this Exclusive License
and Royalty Agreement had not been made and entered into.

            Brunner recognizes that by signing this Agreement, the combination
of this Agreement and the Agreement between Professor Dr. Helmut Borberg and
Licensee attached as Exhibit A will collectively constitute an EXCLUSIVE PATENT
LICENSE AND ROYALTY AGREEMENT by which Borberg and Brunner grant an exclusive
license in the patent to Licensee including the right to sue for past
infringement

1.    Patent Rights. Shall mean any and all of Brunner's rights, title,
      ownership and interests in and to US letters patent 6,245,038 and any and
      all inventions, modifications, continuations-in-part, extensions,
      divisions, improvements, etc. made by Brunner or his agents, in any and
      all areas that relate directly to the Patent, regardless of whether such
      inventions or improvements are patentable or may become parented; all
      inventions. modifications, continuations-in-part, extensions, divisions,
      improvements, etc. shall

<PAGE>

                                      -2-

      automatically be incorporated herein without the payment of any additional
      fees, royalties or any other compensation or considerations of any kind.

2.    Representation by Brunner. Brunner warrants that he, along with Borberg as
      the joint inventor of United States Patent 6,245,038, exclusively owns and
      possesses the Patent and the Patent Rights, and has all right and title
      thereto and that this Patent License and Royalty Agreement is made without
      encumbrance or threat of future interference by others claiming ownership
      therein and that no security interests to any third party exists therein
      or any other agreement to the contrary.

3.    Representation by Licensee. Licensee represents that it is a bona fide
      corporation in good standing in Florida.

4.    Advance Royalty Payments. Licensee agrees to pay Brunner Fifty Thousand
      Dollars ($50,000 USD) annually as an advance and credited against any and
      all Royalty Payments paid in accordance with this License. Such Advance
      Royalty Payments shall be paid to Brunner and in equal payments of Twelve
      Thousand Five-hundred Dollars ($12,500 USD), made quarterly, on or before
      the expiration of Forty-five (45) days after the reporting close of each
      prior calendar quarter. The initial payment of Twelve Thousand
      Five-hundred Dollars ($12,500 USD) shall be due and payable within
      Forty-five (45) Days of the Effective Date herein.

5.    Royalty Payments. Licensee agrees to pay royalties to Brunner totaling
      One-Half Percent (0,5% in USD). Royalty Payments shall be calculated and
      paid based upon Total Net Revenues that Licensee receives from the bona
      fide commercial sales of its Products sold in reliance and dependence upon
      the validity of the Patent's claims and of the Patent Rights in the
      Territory.

6.    Accounting and Timing of Royalty Payments. Upon making each Royalty
      Payment, Licensee shall provide Brunner with a summary of the accounting
      used to determine the amount of Royalty Payment due. Royalty Payments
      shall be made by wire transfer and shall be computed on Total Net Revenues
      received by the Licensee by the reporting close of each calendar quarter
      and distributed and paid to Brunner and on a quarterly basis, on or before
      the expiration of Forty-five (45) days after the reporting close of each
      prior calendar quarter.

7.    Failure to Pay by Licensee. Should Licensee fail to make any payments as
      required herein, and should the Licensee fail to cure the breach created
      thereby, any and all rights, title and ownership to the License provided
      to the Licensee under this Agreement shall be forfeited and any and all
      such rights, title and ownership to the License shall, upon notice of the
      failure to cure the breach, immediately revert to Brunner, and all monies
      paid by Licensee until such date shall be retained by him without
      forfeiture.

8.    Territory. Shall mean the United States and any other jurisdictions
      subject to recognizing any valid claims of the Patent or of the Patent
      Rights.

9.    Total Net Revenues. Shall mean total gross revenues less any discounts,
      rebates, shipping costs, handling costs, transportation insurance costs,
      importation fees, and duties

<PAGE>

                                      -3-

      on any and all Products sold by the Licensee in the Territory and which
      are sold in reliance upon and specifically used in accordance with or
      subject to any of the valid claims of the Patent.

10.   Records. Licensee agrees to keep complete and correct books, accounts and
      records according to Generally Accepted Accounting Principles (GAAP)
      regulations to facilitate computation of Royalty Payments. Brunner or his
      representatives acceptable to Licensee, shall have a full right of
      accounting including the right to confidentially examine Licensee's books
      and records, at all reasonable times and upon reasonable notice, for the
      purpose of verifying the amount of Royalty Payments due.

11.   Products. Shall mean any of Licensee's products, goods or technologies
      sold to unaffiliated third parties in the Territory for the purposes of
      providing extracorporeal therapies for the treatment of the ophthalmic
      diseases as defined by any valid claim(s) of the Patent. In this case,
      Licensee's sale of extracorporeal filters and tubing sets for use in any
      and all ophthalmic indications.

12.   Term. The Royalty Payments shall be due to Brunner beginning with the
      first bona fide commercial sale of any Product in the Territory and may,
      at the discretion of Licensee terminate upon the first of any of the
      following three events to occur: a) All patents of the Patient Rights
      expire, b) All patent claims of the Patent Rights are invalidated, or c) A
      similarly fashioned competitive extracorporeal product, method or
      technology is commercially introduced in the Territory for use in
      ophthalmic indications that could not be deterred by best-efforts
      enforcement/infringement proceedings brought by Licensee against the
      competitive product, method or technology where such proceedings are made
      in reliance in full or in part upon the Patent's claims and or the Patent
      Rights.

13.   Patent Defense. Licensee shall pay for any and all costs incurred for
      patent maintenance, enforcement and defense of the Patent or the Patent
      Rights in the Territory.

14.   Participation. Brunner agrees, in consideration of the premises herein,
      that his executors and administrators will, at any time upon request,
      communicate to the Licensee, its successors and assigns, any facts
      relating to said Patent and Patent Rights, and the history thereof known
      to him or his successors and assigns, and that he will testify as to the
      same in any interference or other proceeding when requested to do so by
      the Licensee, its successors and assigns. Any and all costs of such
      participation by Brunner or his successors and assigns shall be borne by
      Licensee.

15.   Succession. Brunner binds himself and his heirs, executors,
      administrators, employees and legal representatives, as the case may be,
      to execute and deliver to the Licensee, its successors and assigns, any
      further documents or instruments and to do any and all further acts that
      may be deemed necessary by the Licensee, its successors and assigns to
      file applications for improvements and inventions in any country where
      Licensee may elect to file such application(s), and that may be necessary
      to vest in the Licensee, its successors and assigns, the license, rights
      or title herein conveyed, or intended so to be, and to enable such title
      to be recorded in the United States and or foreign countries where

<PAGE>

                                      -4-

      such application(s) may be filed. Any and all costs of such participation
      by Brunner or his successors and assigns shall be borne by Licensee.

16.   Relationship of the Parties: Indemnification. It is agreed that this
      Agreement does not make any Party herein a general or special agent, legal
      representative, subsidiary, joint venturer, partner, employee or servant
      of any other Party herein for any purpose.

17.   Breach and Disputes. Any breaching Party shall have Thirty (30) Days from
      the date of notification to cure such breach. Any dispute between the
      Parties to this Agreement shall be resolved through binding arbitration,
      which shall be governed under the rules and regulations of the American
      Arbitration Association.

18.   Forum, Venue and Governing Law. This agreement shall be governed and
      interpreted under Delaware law (without applying its conflict of law
      principles). Exclusive venue for legal proceedings arising hereunder shall
      be in Hillsborough County, Florida.

19.   Entire Agreement. This Agreement supersedes any prior understanding that
      may have been reached between the Parties and encompasses the entire
      agreement between the Licensee and Brunner with respect to the Patent and
      the Patent Rights. The terms of this Agreement are confidential and shall
      be maintained by the Parties in accordance thereby.

20.   Modification. This Agreement cannot be modified except in writing executed
      mutually between the Parties.

21.   Additional Consideration. This Agreement shall be transformed into an
      EXCLUSIVE PATENT LICENSE and ROYALTY AGREEMENT under the provision that a
      separate Agreement with substantially identical terms and conditions shall
      be concluded with Prof. Dr. Helmut Borberg (Borberg) on or before May 31,
      2002. If such Agreement is not concluded by such date, this Agreement
      shall remain in full force and effect as a NONEXCLUSIVE PATENT LICENSE and
      ROYALTY AGREEMENT between Brunner and Licensee.

            IN WITNESS WHEREOF, the Parties have signed and executed this
Agreement and have caused this Agreement to become effective as of the Effective
Date last executed below.

            OCCULOGIX CORPORATION               prof. Dr. RICHARD BRUNNER

            By:_____________________________    By:_____________________________

            Title:__________________________    Title:__________________________

            Date:___________________________    Date:___________________________

<PAGE>

                PATENT LICENSE AND ROYALTY AGREEMENT (EXHIBIT A)

            THIS AGREEMENT (the "Agreement") is made by and between OccuLogix
Corporation, a Florida Corporation (the "Licensee"), and living in Germany and
listed as inventor [along with Prof. Dr. Richard Brunner ("Brunner") in US
patent application 09/000,917, which is the parent application of US letters
patent 6,245,038 issued Jane 12, 2001 (the "Patent").

            WHEREAS, Borberg [and Brunner] are the sole owners of the Patent and
enjoy all of the rights, title and interests therein, and

            WHEREAS Borberg is aware of the attached NON EXCLUSIVE PATENT
LICENSE and ROYALTY AGREEMENT made between Brunner and Licensee.

            WHEREAS , Borberg desires to license any and all of his rights,
title and interests to the Patent and the Patent Rights derived therefrom to
Licensee, and

            WHEREAS, Borberg recognizes that by signing this Agreement, the
combination of this Agreement and the agreement between Brunner and Licensee
together will become an EXCLUSIVE PATENT LICENSE and ROYALTY AGREEMENT by which
Brunner and Borberg assign an exclusive license in the patent to Licensee.

            WHEREAS, Licensee desires to obtain an exclusive license to all of
Borberg's interests in the Patent and the Patent Rights derived therefrom and to
exclusively own the License to any and all of their rights, title, interests and
ownership to the Patent any and all related patents, rights and inventions that
specifically relate to the Patent whether owned now or at any tame in the future
by Borberg (the "License"), and

            WHEREAS, Borberg shall be eligible to receive any and all
consideration and compensation from the Licensee, such as those pledged to be
made by the Licensee to Borberg under the terms of this Agreement.

            NOW THEREFORE in consideration for guaranteed Advance Royalty
Payments and Royalty Payments as described below, and other good and valuable
consideration, Borberg does hereby exclusively license, in accordance with the
terms set forth below, unto Licensee, its successors and assigns, Borberg's
entire undivided right, title, ownership and interest in and to the Patent and
the invention(s) therein contained (the "Patent Rights"), throughout the
Territory to be held and enjoyed by Licensee its successors and assigns, the
same as it would have been held and enjoyed by Borberg if this License and
Royalty Agreement had not been made and entered into.

1.    Patent Rights. Shall mean any and all of Borberg rights, title, ownership
      and interests in and to US letters patent 6,245,038 and any and all
      inventions, modifications, continuations-in-part, extensions, divisions,
      improvements, etc. made by Borberg or his agents, in any and all areas
      that relate directly to the Patent, regardless of whether such inventions
      or improvements are patentable or may become patented; all inventions,
      modifications, continuations-in-part, extensions, divisions, improvements,
      etc. shall

<PAGE>

                                      -6-

      automatically be incorporated herein without the payment of any additional
      fees, royalties or any other compensation or considerations of any kind.

2.    Representation by Borberg. Borberg warrants that he, along with Brunner,
      exclusively owns and possesses the Patent and the Patent Rights, and has
      all right and title thereto and that this Patent License and Royalty
      Agreement is made without encumbrance or threat of future interference by
      others claiming ownership therein and that no security interests to any
      third party exists therein or any other agreements to the contrary.

3.    Representation by Licensee. Licensee represents that it is a bona fide
      corporation in good standing in Florida.

4.    Advance Royalty Payments. Licensee agrees to pay Borberg Fifty Thousand
      Dollars ($50,000 USD) annually as an advance and credited against any and
      all Royalty Payments paid in accordance with this License. Such Advance
      Royalty Payments shall be paid to Borberg and in equal payments of Twelve
      Thousand Five-hundred Dollars ($12,500 USD), made quarterly, on or before
      the expiration of Forty-five (45) days after the reporting close of each
      prior calendar quarter. The initial payment of Twelve Thousand
      Five-hundred Dollars ($12,500 USD) shall be due and payable within
      Forty-five (45) days of the Effective Date herein.

5.    Royalty Payments. Licensee agrees to pay royalties to Brunner totaling
      One-Half Percent (0,5% in USD). Royalty Payments shall be calculated and
      paid based upon Total Net Revenues that Licensee receives from the bona
      fide commercial sales of its Products sold in reliance and dependence upon
      the validity of the Patent's claims and of the Patent Rights in the
      Territory.

6.    Accounting and Timing of Royalty Payments. Upon making each Royalty
      Payment, Licensee shall provide Brunner with a summary of the accounting
      used to determine the amount of Royalty Payment due. Royalty Payments
      shall be made by wire transfer and shall be computed on Total Net Revenues
      received by the Licensee by the reporting close of each calendar quarter
      and distributed and paid to Brunner and on a quarterly basis, on or before
      the expiration of Forty-five (45) days after the reporting close of each
      prior calendar quarter.

7.    Failure to Pay by Licensee. Should Licensee fail to make any payments as
      required herein, and should the Licensee fail to cure the breach created
      thereby, any and all rights, title and ownership to the License provided
      to the Licensee under this Agreement shall be forfeited and any and all
      such rights, title and ownership to the License shall, upon notice of the
      failure to cure the breach, immediately revert to Brunner, and all monies
      paid by Licensee until such date shall be retained by him without
      forfeiture.

8.    Territory. Shall mean the United States and any other jurisdictions
      subject to recognizing any valid claims of the Patent or of the Patent
      Rights.

9.    Total Net Revenues. Shall mean total gross revenues less any discounts,
      rebates, shipping costs, handling costs, transportation insurance costs,
      importation fees, and duties on any and all Products sold by the Licensee
      in the Territory and which are sold in

<PAGE>

                                      -7-

      reliance upon and specifically used in accordance with or subject to any
      of the valid claims of the Patent.

10.   Records. Licensee agrees to keep complete and correct books, accounts and
      records according to Generally Accepted Accounting Principles (GAAP)
      regulations to facilitate computation of Royalty Payments. Brunner or his
      representatives acceptable to Licensee, shall have a full right of
      accounting including the right to confidentially examine Licensee's books
      and records, at all reasonable times and upon reasonable notice, for the
      purpose of verifying the amount of Royalty Payments due.

11.   Products. Shall mean any of Licensee's products, goods or technologies
      sold to unaffiliated third parties in the Territory for the purposes of
      providing extracorporeal therapies for the treatment of the ophthalmic
      diseases as defined by any valid claim(s) of the Patent. In this case,
      Licensee's sale of extracorporeal filters and tubing sets for use in any
      and all ophthalmic indications.

12.   Term. The Royalty Payments shall be due to Brunner beginning with the
      first bona fide commercial sale of any Product in the Territory and may,
      at the discretion of Licensee terminate upon the first of any of the
      following three events to occur: a) All patents of the Patient Rights
      expire, b) All patent claims of the Patent Rights are invalidated, or c) A
      similarly fashioned competitive extracorporeal product, method or
      technology is commercially introduced in the Territory for use in
      ophthalmic indications that could not be deterred by best-efforts
      enforcement/infringement proceedings brought by Licensee against the
      competitive product, method or technology where such proceedings are made
      in reliance in full or in part upon the Patent's claims and or the Patent
      Rights.

13.   Patent Defense. Licensee shall pay for any and all costs incurred for
      patent maintenance, enforcement and defense of the Patent or the Patent
      Rights in the Territory.

14.   Participation. Borberg agrees, in consideration of the promises herein,
      that he and any of his executors and administrators will, at any time upon
      request, communicate to the Licensee, its successors and assigns, any
      facts relating to said Patent and Patent Rights, and the history thereof,
      known to him or his successors and assigns, and that he will testify as to
      the same in any interference or other proceeding when requested to do so
      by the Licensee, its successors and assigns. Any and all costs of such
      participation by Borberg or his successors and assigns shall be borne by
      Licensee.

15.   Succession. Borberg binds himself and his heirs, executors,
      administrators, employees and legal representatives, the case may be, to
      execute and deliver to the Licensee, its successors and assigns, any
      further documents or instruments and to do any and all further acts that
      may be deemed necessary by the Licensee, its successors and assigns to
      file applications for improvements and inventions in any country where
      Licensee may elect to file such application(s) and that may be necessary
      to vest in the Licensee, its successors and assigns, the license, rights
      or title herein conveyed, or intended so to be, and to enable such title
      to be recorded in the United States and or foreign countries where such
      application(s) may be filed. Any and all costs of such participation by
      Borberg or his successors and assigns shall be borne by Licensee.

<PAGE>

                                      -8-

16.   Relationship of the Parties; Indemnification. It is agreed that this
      Agreement does not make any Party herein a general or special agent, legal
      representative, subsidiary, joint venturer, partner, employee or servant
      of any other Party herein for any purpose.

17.   Breach and Disputes. Any breaching Party shall have Thirty (30) Days from
      the date of notification to cure sure breach. Any dispute between the
      Parties to this Agreement shall be resolved through binding arbitration,
      which shall be governed under the rules and regulations of the American
      Arbitration Association. .

18.   Forum, Venue and Governing Law. This agreement shall be governed and
      interpreted. under Delaware law (without applying its conflict of law
      principles). Exclusive venue for legal proceedings arising hereunder shall
      be in Hillsborough County, Florida.

19.   Entire Agreement. This Agreement supersedes any prior understanding that
      may have been reached between the Parties and encompasses the entire
      agreement between the Licensee and Borberg with respect to the Patent and
      the Patent Rights. The terms of this Agreement are confidential and shall
      be maintained by the Parties in accordance thereby.

20.   Modification. This Agreement cannot be modified except in writing executed
      mutually between the Parties.

            IN WITNESS WHEREOF, the Partise have signed and executed this
Agreement and have caused this Agreement to become affective as of the Effective
Date Last executed below.

            OCCULOGIX CORPORATION               prof. Dr. RICHARD BRUNNER

            By:_____________________________    By:_____________________________

            Title:__________________________    Title:__________________________

            Date:___________________________    Date:___________________________<PAGE>

                                                                    EXHIBIT 10.9

                         DISTRIBUTION SERVICES AGREEMENT

            THIS DISTRIBUTION SERVICES AGREEMENT is made and entered into this
_____ day of May, 2002, by and between Apheresis Technologies, Inc., a Florida
corporation located at 612 Florida Avenue, Palm Harbor Florida (the "Provider"),
and OccuLogix Corporation, a Florida corporation ("OccuLogix").

                                   WITNESSETH:

            WHEREAS, the Provider is a provider of customer service,
warehousing, order fulfillment, billing and shipping services; and

            WHEREAS, OccuLogix is initiating marketing into Canada and Mexico
and is in the process of obtaining FDA approval for the sale and distribution of
its Rheopheresis product group, including certain disposable filters, tubing and
pump machines (the "Product'); and

            WHEREAS, OccuLogix desires to obtain from the Provider certain
services; and

            WHEREAS, the Provider desires to provide certain services to
OccuLogix.

            NOW, THEREFORE, in consideration of the mutual obligations and
promises set forth herein, the Provider and OccuLogix agree as follows:

1.    Term. The term of this Agreement shall commence on the date hereof and
      shall continue until the date ten years subsequent to the "Approval Date."
      For purposes of this Agreement, the term "Approval Date" shall mean the
      date on which the FDA grants to OccuLogix PMA approval to sell the Product
      in the US; provided, however, that if the Approval Date shall not have
      occurred by May 1, 2012, this Agreement shall terminate.

2.    Services. The parties agree that the Provider shall be the exclusive
      provider to OccuLogix of warehousing, order fulfillment, shipping, billing
      services and customer service related to shipping and billing all as
      further provided herein.

3.    Warehousing. OccuLogix, at its expense, shall ship a quantity of Product
      inventory determined by OccuLogix to the premises of the Provider at 612
      Florida Avenue, Palm Harbor Florida, or other such facility as deemed
      necessary or appropriate by the Provider. The Provider shall store,
      maintain, manage and account for such inventory in accordance with
      warehouse procedures to be agreed upon from time to time by the parties,
      but will at a minimum materially satisfy all FDA and or other regulatory
      requirements as may be necessary. As such, the Provider agrees to remain
      in compliance with all pertinent regulations at all times.

4.    Order Fulfillment; Customer Service. Orders for the Product, whether
      received by OccuLogix or directly by the Provider, shall be forwarded to
      the Provider for processing. Upon Provider's receipt of confirmation of
      the purchase from OccuLogix, the order shall be picked from inventory on a
      FIFO basis, packed, labeled and otherwise prepared for

<PAGE>

                                      -2-

      shipping by the Provider, all in accordance with order fulfillment
      procedures to be agreed upon from time to time by the parties.

5.    Shipping; Billing. The Provider agrees to ship all orders processed
      hereunder in accordance with shipping procedures to be agreed upon from
      time to time by the parties. At the time of shipment, the Provider shall
      invoice the customer in accordance with procedures approved by OccuLogix
      and shall enter such invoice information into a billing and collection
      system specified by OccuLogix.

6.    Reporting. The Provider shall report its activities hereunder to OccuLogix
      in reasonable detail on a daily basis using such report formats as are
      agreed upon from time to time by the parties.

7.    Fees. OccuLogix shall pay to the Provider service fees for the services
      provided hereunder in accordance with the following terms:

            (a)   OccuLogix shall pay to the Provider a basic service fee of 5%
                  of the cost of delivered goods. For purposes of this
                  Agreement, the tern "cost of delivered goods" shall mean the
                  purchase price paid by OccuLogix for the goods, together with
                  all shipping and related charges to the Provider's warehouse.
                  For the purposes of this agreement, the basic service fee
                  shall be compensation for all preparation and handling of
                  shipments, customer service of shipping, handling and returns,
                  all invoicing activities and warehousing (including labor
                  costs for employees directly involved in the performance of
                  such services).

            (b)   In addition, Occulogix shall pay the Provider the cost of
                  shipping between Provider and customer including any required
                  packaging and labeling (materials and labor).

            (c)   The Provider shall invoice OccuLogix for services monthly.
                  Invoices are due 30 days after the date of the invoice. The
                  invoice shall be in a format with sufficient detail for use by
                  OccuLogix for financial reporting and management planning
                  purposes.

8.    Examination of Records. Upon not less than 48 hours notice, each party
      shall be entitled to examine the records of the other party regarding the
      performance of the parties under this Agreement on regular business days
      (Monday through Friday) and during regular business hours (8:30 A.M. -
      5:00 P.M. Eastern Time).

9.    Notices. Notice by either party will be made only in writing by certified
      mail, return receipt requested or facsimile addressed to the other party
      and will be considered given as of the time it is received. Addresses for
      notices are as follows:

                                               Provider:
                                               Apheresis Technologies, Inc

<PAGE>

                                      -3-

                                               612 Florida Avenue
                                               Palm Harbor FL 34683
                                               FAX: 784-0898

                                               OccuLogix Corporation
                                               612 Florida Avenue
                                               Palm Harbor FL 34683
                                               FAX: 784-0898

            Changes to the notice addresses may be accomplished by notice in
accordance with this paragraph.

10.   Risk of Loss and Insurance.

            (a)   The risk of loss of OccuLogix inventory shall at all times be
                  borne by OccuLogix; provided, however, that any damage
                  occurring as a result of negligence of the Provider shall be
                  the responsibility of the Provider.

            (b)   Each party shall be responsible for maintaining insurance upon
                  its own inventory, equipment, furniture, fixtures, supplies
                  and other property located upon the premises of the Provider.

            (c)   Each party shall carry General Liability Insurance in the
                  amount of not less than $1,000,000 per occurrence/$2,000,000
                  aggregate during the term of this agreement.

            (d)   Each party shall furnish evidence to the other party of its
                  compliance with this paragraph.

11.   Confidential Information. The parties hereto consider this Agreement and
      all of its terms and conditions to be confidential. Except as may have
      been, or shall be, authorized in writing, or as hereinafter mentioned,
      each of the parties hereto shall keep confidential and shall not use
      otherwise than in the performance of this Agreement and shall take all
      reasonable steps to insure that its employees keep confidential and not
      use, all information supplied to them or which they have learned during
      the negotiations leading to this Agreement or learned hereafter concerning
      the business of the other. This obligation shall survive the termination
      of this Agreement and for 5 years after any termination of this Agreement.
      Nothing herein shall preclude disclosure of information to the extent that
      the disclosure is required to be made under laws or regulations in force
      and applicable to the party, or pursuant to a subpoena; provided, however,
      the party required to disclose any such confidential information shall
      immediately, upon receipt of a subpoena, notice, demand or order to
      produce the information, and prior to complying with the subpoena, notice,
      demand, or order, notify the other party of said subpoena, notice, demand
      or order and at the request of the other party, contest or join with the
      other party in contesting the propriety and/or authority of disclosing the
      information. Each party shall bear its own costs of complying with the
      provisions of this paragraph.

<PAGE>

                                      -4-

12.   Independent Contractor. The parties each agree and acknowledge that this
      Agreement does not constitute a joint venture or partnership. This
      Agreement has been reached by arms' length negotiations and is an
      independent services contract in which the Provider acts as an independent
      contractor.

13.   Assignability. This Agreement and the rights and obligations hereunder may
      not be assigned by either party without the prior written consent of the
      other party.

14.   Force Majeure. Except for the payment of money due hereunder, the Provider
      and OccuLogix shall be excused for failure to perform under this Agreement
      where such failure results from circumstances beyond the affected party's
      control including, without limitation, such circumstances as fire, storm,
      flood, earthquake, strikes, work stoppages or slow downs, delay or failure
      of transportation or supplies, acts of the public enemy, acts of God or
      acts, regulations, priorities or actions of the United States, a state or
      any local government or agents or instrumentalities thereof.

15.   Governing Law. This Agreement shall be interpreted, and the rights,
      obligations and liabilities of the parties determined in accordance with
      the laws of the State of Florida (without regard to the conflicts of laws
      provisions thereof). The parties agree that any litigation arising out of
      this Agreement or performance of it by either party shall be litigated in
      either the Circuit Court of Pinellas County, Florida, or the United States
      District Court for the Middle District of Florida, Tampa Division.

16.   Amendments. No alteration, modification or change of this Agreement shall
      be valid except by an agreement in writing executed by both parties
      hereto.

17.   Dispute Resolution. The Provider and OccuLogix will attempt to settle any
      claim or controversy arising out of this Agreement through consultation
      and negotiation in good faith and a spirit of mutual cooperation. If those
      attempts fail, then the dispute will be mediated by a mutually acceptable
      mediator to be chosen by the Provider and OccuLogix within 45 days after
      written notice by either to the other demanding mediation. Neither party
      may unreasonably withhold consent to the selection of a mediator, and the
      Provider and OccuLogix will share the cost of the mediation equally. By
      mutual agreement, the Provider and OccuLogix may postpone mediation until
      some specified but limited discovery about the dispute has been completed.
      The parties may also agree to replace mediation with some other form of
      alternative dispute resolution. Any dispute which cannot be resolved
      between the parties through negotiation, mediation or other form of agreed
      alternative dispute resolution within 120 days of the date of the initial
      demand for it by one of the parties may then be submitted to the courts
      for resolution. Nothing in this section will prevent either party from
      resorting to judicial proceedings if (A) good faith efforts to resolve the
      dispute under these procedures have been unsuccessful, (B) interim relief
      from a court is necessary to prevent serious and irreparable injury to one
      party or to others, or (C) litigation is required to be filed prior to the
      running of the applicable statute of limitations. The use of any
      alternative dispute resolution procedure will not be construed under the
      doctrines of laches, waiver or estoppel to affect adversely the rights of
      either party.

<PAGE>

                                      -5-

18.   Severability. In the event that any provision or any portion of any
      provision of this agreement is held illegal, unenforceable, or invalid by
      any Court, such provision or portion thereof shall be deemed to be deleted
      from this agreement, and the validity of the remainder of this agreement
      shall remain unaffected thereby.

19.   Entire Agreement. This Agreement constitutes the entire Agreement and
      understanding of the parties with regard to the matters covered herein.

20.   Attorneys' Fees. If any suit, action or arbitration is initiated by any
      party to enforce this Agreement or otherwise with respect to the subject
      matter of this Agreement, the prevailing party in such suit, action or
      arbitration shall be entitled to recover reasonable attorneys' fees and
      expenses, including but not limited to travel, incurred in the preparation
      and prosecution or defense of such suit, action or arbitration, and if any
      appeal is taken from the decision of the trial court or arbitrator,
      reasonable attorneys' fees for such appeal.

21.   Events of Default. The occurrence of one or more of the following events
      (an "Event of Default") shall constitute a default hereunder:

            (a)   Covenants. The failure of either party hereto to perform or
                  observe any covenant, term or condition binding on it
                  contained herein if such default is not remedied within 30
                  days after written notice thereof from the non-defaulting
                  party.

            (b)   Liquidation; Bankruptcy. In the case of the Provider, the
                  liquidation or dissolution of the Provider, or the filing by
                  or against the Provider of a petition seeking relief under the
                  United States Bankruptcy Code, as amended, or under any other
                  insolvency act or law.

            (c)   Business Suspension. In the case of the Provider, the
                  suspension of the Provider's business by a governmental agency
                  or instrumentality, including without limitation the United
                  States Food and Drug Administration, as a result of any
                  alleged violation by the Provider of any law, rule or
                  regulation administered or promulgated by such agency or
                  instrumentality.

22.   Remedies. Upon the occurrence of any Event of Default, and at any time
      thereafter as long as the Event of Default is continuing, the
      nondefaulting party may terminate this Agreement and may pursue all
      rights, remedies or recourses available to such party at law, in equity or
      otherwise. Such remedies are cumulative, and exercisable concurrently, and
      may be pursued singularly, successively or together and may be exercised
      as often as occasion therefore shall arise.

<PAGE>

                                      -6-

            IN WITNESS WHEREOF, each of the parties hereto have caused this
Agreement to be signed by its respective duly authorized representative.

                                               Apheresis Technologies, Inc.

                                               By:______________________________

                                               OccuLogix Corporation

                                               By:______________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]